Quanterix Announces Board and Leadership Changes for Next Growth Phase

Appoints Garret Hampton and Alan Sachs to the Board

Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director

Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), an organization reworking healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, right this moment introduced a collection of management and governance enhancements designed to help the Company’s subsequent part of development. These modifications embody the appointment of two extremely completed life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company’s Board of Directors, efficient instantly.

Dr. Hampton most not too long ago served as President, Clinical Next Generation Sequencing and Oncology at Thermo Fisher Scientific. Dr. Sachs is the previous Chief Medical Officer and Chief Scientific Officer of Thermo Fisher Scientific.

The Company additionally introduced that Bill Donnelly, beforehand the non-Executive Chair of the Board, has been appointed Executive Chair, and Jeffrey Elliott, a present member of the Board, has been appointed to the newly created position of Lead Independent Director.

As Executive Chair, Mr. Donnelly will work carefully with the Company’s management workforce and present help in choose strategic and operational areas. This construction permits Chief Executive Officer Masoud Toloue to proceed advancing the Company’s key strategic initiatives, together with increasing its blood- and tissue-based biomarker menu, launching LucentAD Complete for Alzheimer’s prognosis, and accelerating development synergies from the Akoya acquisition.

Additionally, Paul Meister and David Walt, Ph.D. are stepping down from the Board after a few years of service, efficient instantly.

With these modifications, the Quanterix Board now includes 9 members, seven of whom are unbiased.

“On behalf of the Company, I’m happy to welcome Garret and Alan to the Board.” mentioned Bill Donnelly, Executive Chair of the Board. “Their deep experience in diagnostics, life sciences and product innovation will convey beneficial views to the Board. As we transfer past the combination stage and shift our focus towards development, their mixture of scientific perception, market data, and expertise in figuring out and executing on development alternatives might be invaluable.”

Mr. Donnelly added, “I’d additionally wish to thank Paul and David for their years of service and dedication to Quanterix. As our founding scientist and a pioneer in precision medication, David has helped revolutionize the best way pathologists detect and deal with illness, whereas Paul, as a number one life sciences investor, has supplied numerous insights and contributions to our technique. Both Paul and David have been instrumental within the Company’s development, and we’re deeply appreciative of the regular oversight and steerage they supplied throughout their tenures. We want all of them the very best.”

“I’m excited to work with Garret and Alan who convey distinctive technical data and enterprise management to our Board,” mentioned Masoud Toloue, CEO of Quanterix. “Bill’s expanded position will additional strengthen our operational alignment and assist speed up the achievement of our development initiatives. Together, these modifications place the Company for continued management within the instruments and diagnostics sector, advancing our mission to enhance well being outcomes for sufferers worldwide.”

“I sit up for working carefully with Masoud and the remainder of the management workforce at Quanterix to advance our strategic priorities,” added Mr. Donnelly. “With the acquisition of Akoya Biosciences now full and the combination efforts advancing effectively, Quanterix is coming into a brand new period. The Board and I are assured within the Company’s skill to ship significant worth within the coming years for our shareholders and for sufferers, companions, and different stakeholders.”

The submit Quanterix Announces Board and Leadership Changes for Next Growth Phase first appeared on AI-Tech Park.